Cutera (NASDAQ:CUTR) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Cutera (NASDAQ:CUTR) in a research report released on Monday morning. The brokerage issued a sell rating on the medical device company’s stock.

A number of other equities analysts have also weighed in on CUTR. Piper Sandler reaffirmed a “neutral” rating and issued a $1.00 price objective (down previously from $3.00) on shares of Cutera in a research note on Friday, August 9th. Stephens cut their price objective on Cutera from $10.00 to $5.00 and set an “overweight” rating for the company in a research report on Friday, August 9th.

Cutera Price Performance

NASDAQ CUTR opened at $0.30 on Monday. The stock’s 50-day moving average price is $0.64 and its 200-day moving average price is $1.20. The company has a market capitalization of $6.10 million, a P/E ratio of -0.05 and a beta of 1.35. Cutera has a 52 week low of $0.28 and a 52 week high of $4.97.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Squarepoint Ops LLC increased its position in Cutera by 164.5% during the second quarter. Squarepoint Ops LLC now owns 113,964 shares of the medical device company’s stock valued at $172,000 after acquiring an additional 70,870 shares during the last quarter. Bank of Montreal Can boosted its holdings in Cutera by 14.2% during the 2nd quarter. Bank of Montreal Can now owns 282,704 shares of the medical device company’s stock valued at $455,000 after acquiring an additional 35,248 shares during the period. Ground Swell Capital LLC purchased a new position in Cutera in the 2nd quarter worth about $37,000. Bayesian Capital Management LP bought a new stake in Cutera during the 1st quarter valued at about $33,000. Finally, BNP Paribas Financial Markets raised its stake in shares of Cutera by 7.1% during the first quarter. BNP Paribas Financial Markets now owns 75,833 shares of the medical device company’s stock valued at $111,000 after acquiring an additional 5,017 shares in the last quarter. Institutional investors own 90.70% of the company’s stock.

About Cutera

Cutera, Inc provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for skin revitalization; truFlex, a bio-electrical muscle stimulation device designs to strengthen, firm and tone the abdomen, buttocks, and thighs; and excel V/V+, a vascular and benign pigmented lesion treatment platform.